Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response
Wednesday, 14 April 2021, 14:28:27
Galectin Therapeutics Inc (NASDAQ: GALT ) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma. The study assessing belapectin combined with Merck's & Co's (NYSE: MRK ) … Full story available on Benzinga.com
Palantir is continuing its push into life sciences with customers like Merck and Sanofi, as the secretive data analysis firm expands beyond defense deals
Tuesday, 13 April 2021, 19:49:02
Summary List Placement In a continued push to expand its business beyond the sometimes-controversial federal defense and intelligence contracts it's best-known for, $42 billion big data company Palantir is making a new push into industries including life sciences and manufacturing. That push comes in the form of new capabilities for Palantir Foundry, its product for the private sector, which will be showcased at a company event it calls Double Click on Wednesday. Clients of Palantir Foundry include pharmaceutical companies Merck and Sanofi , according to a Palantir spokesperson, and the company is increasingly focusing on developing its artificial intelligence and machine learning modeling capabilities and controls for customers across industries and sectors, including government agencies. Palantir's expansion into life sciences hints at the expanding market opportunity for cloud companies in healthcare and pharmaceuticals, especially amid the pandemic, as we saw with Microsoft's planned $19.7 billlion acquisition of AI and voice communications firm Nuance, announced this week.
— Business Insider
Goldman Sachs names 40 stocks to buy before they surge to meet its higher price targets – including 5 with more than 50% upside
Sunday, 11 April 2021, 12:30:00
Summary List Placement Markets saw a strong start to the second quarter. The S&P 500 rose to a record high on April 1 and surpassed 4,000 points for the first time on the back of increased confidence in the economy that stemmed from vaccinations and Biden's infrastructure plan. During the first quarter, all 11 stock-market sectors saw gains . Cyclicals were the biggest winners, with the energy, financials, and industrial sectors posting double-digit gains during that period given that they are closely correlated with the fluctuations of the economy. And although the utilities, tech, and consumer staples areas still enjoyed some returns, they ended up performing the worst. However, since reaching record highs, stocks have proceeded to trade in a flat manner. But that might change soon enough as earnings season kicks off this week with big banks like JPMorgan and Bank of America sharing their financial reports with investors. Investors assess earnings to determine a company's profitability and use earnings per share as a metric to estimate its valuation.
— Business Insider
Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer (IMMP)
Thursday, 8 April 2021, 18:02:31
Summary List Placement Immutep jumped as much as 13% to two-week highs on Thursday after the biotechnology company announced that its lead drug candidate for recurrent or metastatic head and neck cancer has received a fast track status from the US Food and Drug Administration. Immutep was up 8% to $3.45 as of 12:00 p.m. ET, having risen to a session peak of $3.59 earlier in the day, its highest since March 25. Immutep is listed on the Australian Securities Exchange and on the Nasdaq. The drug candidate, eftilagimod alpha or efti, is a soluble LAG-3 protein aimed to become the first line treatment of recurrent or metastatic head and neck cancer. It was given a fast track status — a designation awarded by the FDA to expedite its development and review — due to its potential to address an unmet medical need, the company said in a statement Thursday. Recurrent is when cancer comes back after treatment, while metastatic is when cancer spread to a distant part from where it started in the body, according to the National Cancer Institute .
— Business Insider Markets
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
Thursday, 8 April 2021, 14:26:14
Merck & Co Inc (NYSE: MRK ) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic … Full story available on Benzinga.com
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.